Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
London School of Economics and Political Science · London School of Hygiene & Tropical Medicine · +1 more institution
Abstract
The mean cost of developing a new drug has been the subject of debate, with recent estimates ranging from $314 million to $2.8 billion.
To estimate the research and development investment required to bring a new therapeutic agent to market, using publicly available data. DESIGN AND SETTING: Data were analyzed on new therapeutic agents approved by the US Food and Drug Administration (FDA) between 2009 and 2018 to estimate the research and development expenditure required to bring a new medicine to market. Data were accessed from the US Securities and Exchange Commission, Drugs@FDA database, and ClinicalTrials.gov, alongside published data on clinical trial success rates. EXPOSURES: Conduct of preclinical and clinical studies of new therapeutic agents. MAIN OUTCOMES AND MEASURES: Median and mean research and development spending on new therapeutic agents approved by the FDA, capitalized at a real cost of capital rate (the required rate of return for an investor) of 10.5% per year, with bootstrapped CIs. All amounts were reported in 2018 US dollars.
Citation impact
- FWCI
- 257.81
- Percentile
- 100%
- References
- 28
Authors
3Topics & keywords
- Medicine
- Investment (military)
- Clinical trial
- Drug development
- Clinical research
- Actuarial science
- Drug
- Pharmacology
- Partnerships for the goals